INTRODUCTION {#s1}
============

Diabetes mellitus significantly increases the risk of cancer and noncancer deaths \[[@R1]--[@R4]\]. According to global statistics, there were 1.8 million new cases of lung cancer in the world in 2012, accounting for about 13% of all cancer diagnoses \[[@R5]\]. In Taiwan, lung cancer represents approximately 15% and 8% of all cancers in men and women, respectively \[[@R6]\]. Although the incidence of lung cancer is decreasing in men and increasing in women in the whole world \[[@R5]\], it is increasing steadily in both sexes in Taiwan \[[@R6],[@R7]\]. Smoking is the most important risk factor, but air pollution, fumes from cooking and other occupational and environmental exposure to carcinogens such as asbestos, arsenic, radon and polycyclic aromatic hydrocarbons are also potential risk factors \[[@R5]\].

Patients with type 2 diabetes mellitus (T2DM) suffer from a higher risk of various types of cancer including lung cancer \[[@R7],[@R8]\]. Epidemiological studies show that metformin may reduce the risk of several types of cancer, including thyroid cancer \[[@R9]\], oral cancer \[[@R10]\], esophageal cancer \[[@R11]\], gastric cancer \[[@R12]\], colon cancer \[[@R13]\], kidney cancer \[[@R14]\], bladder cancer \[[@R15]\], prostate cancer \[[@R16]\], breast cancer \[[@R17]\], endometrial cancer \[[@R18]\], ovarian cancer \[[@R19]\] and cervical cancer \[[@R20]\]. However, whether metformin may reduce the risk of lung cancer remains to be answered.

There are some observational studies but the conclusions are inconsistent. Tsai et al. reported a reduced risk of lung cancer associated with metformin use \[[@R21]\], but Sakoda et al. did not find such a beneficial effect \[[@R22]\]. Meta-analyses also showed controversial results. In 2013, Wang et al. estimated a pooled relative risk of 0.91 (95% confidence interval: 0.80-1.03) from 7 observational studies \[[@R23]\]. In 2014, three meta-analyses concluded differently. Zhang et al. pooled the data from 4 studies and showed a significantly lower risk associated with metformin use (pooled relative risk: 0.71, 95% confidence interval: 0.55-0.95, *P*=0.02) \[[@R24]\]. However, by including 15 (11 cohort and 4 case-control) observational studies, Nie et al. reported a null association with an adjusted odds ratio of 0.99 (95% confidence interval: 0.87-1.12) \[[@R25]\]. The meta-analysis by Wu et al. (including 15 studies: 11 cohort, 2 case-control and 2 randomized controlled trials) suggested a 15% risk reduction (odds ratio 0.85, 95% confidence interval: 0.77-0.92), but this could not be demonstrated in smoking-adjusted subgroup \[[@R26]\]. In 2015, the latest meta-analysis including 8 observational studies by Zhu et al. suggested a significant 16% risk reduction (relative risk 0.84, 95% confidence interval: 0.73-0.97) \[[@R27]\].

By using the reimbursement databases of the Taiwan\'s National Health Insurance (NHI), the present study aimed at clarifying whether metformin use in patients with T2DM might reduce the risk of lung cancer. The tertiles of cumulative duration of metformin therapy were used to evaluate a dose-response relationship. To reduce "prevalent user bias" \[[@R28]\], only patients with newly diagnosed diabetes and new users of metformin were recruited. To reduce "immortal time bias" during the initial period of follow-up when the outcome can not occur \[[@R28]\], recruited patients should have been prescribed antidiabetic drugs for at least two times, and those who were followed up for \<1 year were excluded. To reduce the residual confounding from the differences in baseline characteristics, Cox regression models incorporated with the inverse probability of treatment weighting (IPTW) using propensity score (PS) were created to estimate the hazard ratios \[[@R29]\] and additional analyses were conducted in a sample of 1:1 matched-pairs.

RESULTS {#s2}
=======

There were 15414 never users and 280159 ever users of metformin in the original sample (Figure [1](#F1){ref-type="fig"}, Table [1](#T1){ref-type="table"}). All characteristics differed significantly, except for hypertension, pioglitazone, Epstein-Barr virus (EBV)-related diagnoses and hepatitis B virus (HBV) infection (Table [1](#T1){ref-type="table"}). There were 15414 never users and 15414 ever users in the matched-pairs (Figure [1](#F1){ref-type="fig"}, Table [1](#T1){ref-type="table"}). Except for age, insulin, sulfonylurea, meglitinide and alcohol-related diagnoses, all other variables did not differ significantly between metformin ever and never users (Table [1](#T1){ref-type="table"}). While examining the standardized differences, 11 of the variables had values \>10% in the original sample, but none had a value \>10% in the matched sample. Therefore, residual confounding from the variables was less likely in the matched sample.

![Flowchart showing the procedure in selecting the original sample and the matched sample into the study](oncotarget-08-41132-g001){#F1}

###### Characteristics of metformin never users and ever users

  Variable                                                                                 Original sample (N=295573)   Matched sample (N=30828)                                                                                   
  ---------------------------------------------------------------------------------------- ---------------------------- -------------------------- -------- ------- ---------- -------- ------- ------- ------- ------- ---------- -------
  **Demographic data**                                                                                                                                                                                                             
  Age (years)\*                                                                            63.76                        10.41                      61.43    10.21   \<0.0001   -23.07   63.76   10.41   64.11   9.87    0.0020     4.23
  Sex (men)                                                                                8819                         57.21                      150517   53.73   \<0.0001   -7.27    8819    57.21   8767    56.88   0.5496     -0.92
  Occupation                                                                                                                                                                                                                       
   I                                                                                       6033                         39.14                      113083   40.36   \<0.0001            6033    39.14   5952    38.61   0.5105     
   II                                                                                      3075                         19.95                      64289    22.95              7.66     3075    19.95   3074    19.94              -0.05
   III                                                                                     3236                         20.99                      54670    19.51              -3.68    3236    20.99   3341    21.68              1.85
   IV                                                                                      3070                         19.92                      48117    17.17              -7.48    3070    19.92   3047    19.77              -0.49
  Living region                                                                                                                                                                                                                    
   Taipei                                                                                  5210                         33.80                      94703    33.80   \<0.0001            5210    33.80   5198    33.72   0.6683     
   Northern                                                                                1565                         10.15                      33569    11.98              6.01     1565    10.15   1570    10.19              -0.03
   Central                                                                                 2681                         17.39                      49963    17.83              1.23     2681    17.39   2615    16.97              -1.14
   Southern                                                                                2692                         17.46                      44872    16.02              -4.01    2692    17.46   2782    18.05              1.68
   Kao-Ping and Eastern                                                                    3266                         21.19                      57052    20.36              -2.01    3266    21.19   3249    21.08              0.00
  **Major comorbidities**                                                                                                                                                                                                          
  Hypertension                                                                             12627                        81.92                      228657   81.62   0.3456     -0.81    12627   81.92   12650   82.07   0.7332     0.60
  Dyslipidemia                                                                             11209                        72.72                      233135   83.22   \<0.0001   26.93    11209   72.72   11139   72.27   0.3720     -0.61
  Obesity                                                                                  413                          2.68                       16082    5.74    \<0.0001   15.36    413     2.68    376     2.44    0.1821     -1.36
  **Diabetes-related complications**                                                                                                                                                                                               
  Nephropathy                                                                              5330                         34.58                      75028    26.78   \<0.0001   -18.17   5330    34.58   5335    34.61   0.9523     -0.64
  Eye disease                                                                              2911                         18.89                      87493    31.23   \<0.0001   29.15    2911    18.89   2786    18.07   0.0666     -2.54
  Stroke                                                                                   5085                         32.99                      80963    28.90   \<0.0001   -9.35    5085    32.99   5180    33.61   0.2509     1.27
  Ischemic heart disease                                                                   7352                         47.70                      127487   45.51   \<0.0001   -4.58    7352    47.70   7324    47.52   0.7495     -0.23
  Peripheral arterial disease                                                              3604                         23.38                      70404    25.13   \<0.0001   4.23     3604    23.38   3583    23.25   0.7773     -0.43
  **Antidiabetic drugs**                                                                                                                                                                                                           
  Insulin                                                                                  1243                         8.06                       5814     2.08    \<0.0001   -29.03   1243    8.06    943     6.12    \<0.0001   -9.02
  Sulfonylurea                                                                             11298                        73.30                      185722   66.29   \<0.0001   -12.17   11298   73.30   11844   76.84   \<0.0001   9.58
  Meglitinide                                                                              1248                         8.10                       10100    3.61    \<0.0001   -20.17   1248    8.10    1111    7.21    0.0033     -3.14
  Acarbose                                                                                 1713                         11.11                      14193    5.07    \<0.0001   -21.80   1713    11.11   1654    10.73   0.2813     -2.19
  Rosiglitazone                                                                            469                          3.04                       12833    4.58    \<0.0001   8.46     469     3.04    441     2.86    0.3461     -1.29
  Pioglitazone                                                                             391                          2.54                       6779     2.42    0.3582     -0.09    391     2.54    389     2.52    0.9422     -0.39
  **Potential risk factors of cancer**                                                                                                                                                                                             
  COPD                                                                                     7659                         49.69                      136662   48.78   0.0280     -2.17    7659    49.69   7640    49.57   0.8287     -0.18
  Tobacco abuse                                                                            431                          2.80                       11028    3.94    \<0.0001   6.47     431     2.80    403     2.61    0.3256     -1.13
  Alcohol-related diagnoses                                                                1178                         7.64                       19452    6.94    0.0009     -3.36    1178    7.64    1083    7.03    0.0379     -2.79
  History of HP infection                                                                  5141                         33.35                      84180    30.05   \<0.0001   -7.84    5141    33.35   5102    33.10   0.6372     -0.92
  EBV-related diagnoses                                                                    109                          0.71                       1997     0.71    0.9352     0.06     109     0.71    105     0.68    0.7838     -0.31
  HBV infection                                                                            681                          4.42                       11704    4.18    0.1469     -1.53    681     4.42    631     4.09    0.1583     -1.84
  HCV infection                                                                            998                          6.47                       14304    5.11    \<0.0001   -6.39    998     6.47    951     6.17    0.2714     -1.35
  **Medications that are commonly used in diabetes patients and may affect cancer risk**                                                                                                                                           
  ACEI/ARB                                                                                 10731                        69.62                      204108   72.85   \<0.0001   7.37     10731   69.62   10657   69.14   0.3605     -0.95
  Calcium channel blocker                                                                  9705                         62.96                      166164   59.31   \<0.0001   -7.70    9705    62.96   9770    63.38   0.4428     0.96
  Statin                                                                                   8373                         54.32                      184811   65.97   \<0.0001   24.99    8373    54.32   8299    53.84   0.3977     -0.88
  Fibrate                                                                                  5303                         34.40                      120199   42.90   \<0.0001   18.18    5303    34.40   5259    34.12   0.5975     -0.36
  Aspirin                                                                                  8849                         57.41                      171328   61.15   \<0.0001   7.81     8849    57.41   8839    57.34   0.9083     0.04

\*Age is expressed as mean and standard deviation

Refer to Materials and Methods for the classification of occupation

SD: standardized difference, COPD: chronic obstructive pulmonary disease, HP: *Helicobacter pylori*, EBV: Epstein-Barr virus, HBV: hepatitis B virus, HCV: hepatitis C virus, ACEI/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker

Table [2](#T2){ref-type="table"} shows the incidences of lung cancer by metformin exposure and the hazard ratios comparing exposed to unexposed patients in the original sample and the matched sample, respectively. The respective incidence of lung cancer for ever users and never users was 173.36 and 292.65 per 100,000 person-years in the original sample; and was 211.71 and 292.65 per 100,000 person-years in the matched sample. The overall hazard ratio (95% confidence interval) of 0.586 (0.509-0.674) in the original sample and 0.717 (0.584-0.881) in the matched sample suggested a significantly lower risk of lung cancer associated with metformin use. When examining lung cancer by the tertiles of cumulative duration, there was a trend of decreasing incidence with longer duration of exposure. A significantly lower risk was observed for the third tertiles, but the first tertiles were associated with a significantly higher risk, in both the original sample and the matched sample.

###### Incidences of lung cancer and hazard ratios by metformin exposure

  Metformin use                                                       *n*    *N*      Person-years   Incidence rate (per 100,000 person-years)   HR      95% CI          *P* value
  ------------------------------------------------------------------- ------ -------- -------------- ------------------------------------------- ------- --------------- -----------
  **Original sample**                                                                                                                                                    
   Never users                                                        211    15414    72099.19       292.65                                      1.000                   
   Ever users                                                         2365   280159   1364192.16     173.36                                      0.586   (0.509-0.674)   \<0.0001
  **Tertiles of cumulative duration of metformin therapy (months)**                                                                                                      
   Never users                                                        211    15414    72099.19       292.65                                      1.000                   
   \<22.60                                                            1190   92347    358747.29      331.71                                      1.163   (1.005-1.348)   0.0433
   22.60-46.67                                                        854    92759    464388.82      183.90                                      0.612   (0.526-0.711)   \<0.0001
   ≥46.67                                                             321    95053    541056.05      59.33                                       0.176   (0.148-0.210)   \<0.0001
  **Matched sample**                                                                                                                                                     
   Never users                                                        211    15414    72099.19       292.65                                      1.000                   
   Ever users                                                         158    15414    74631.29       211.71                                      0.717   (0.584-0.881)   0.0016
  **Tertiles of cumulative duration of metformin therapy (months)**                                                                                                      
   Never users                                                        211    15414    72099.19       292.65                                      1.000                   
   \<22.60                                                            80     5085     19517.80       409.88                                      1.465   (1.131-1.897)   0.0038
   22.60-47.13                                                        57     5088     25246.49       225.77                                      0.758   (0.566-1.016)   0.0641
   ≥47.13                                                             21     5241     29867.01       70.31                                       0.228   (1.460-0.357)   \<0.0001

*n*: case number of incident lung cancer, *N*: case number followed

HR: hazard ratio, CI: confidence interval

Table [3](#T3){ref-type="table"} shows the overall hazard ratios in the original sample as sensitivity analyses after excluding patients with certain risk factors of cancer. In all analyses, a significantly lower risk of lung cancer associated with metformin use was observed.

###### Sensitivity analyses estimating hazard ratios for lung cancer for ever versus never users of metformin after excluding patients with certain risk factors of cancer

  Model                                                             *n*/*N* in ever users   *n*/*N* in never users   HR      95% CI          *P* value
  ----------------------------------------------------------------- ----------------------- ------------------------ ------- --------------- -----------
  Excluding patients who developed other cancers during follow-up   2365 / 262556           211 / 14150              0.578   (0.502-0.665)   \<0.0001
  Excluding patients with COPD/tobacco abuse                        751 / 138825            61 / 7583                0.649   (0.500-0.842)   0.0012
  Excluding patients with alcohol-related diagnoses                 2165 / 260707           198 / 14236              0.570   (0.493-0.660)   \<0.0001
  Excluding patients with HP infection                              1546 / 195979           135 / 10273              0.578   (0.484-0.689)   \<0.0001
  Excluding patients with EBV-related diagnoses                     2346 / 278162           207 / 15305              0.593   (0.514-0.683)   \<0.0001
  Excluding patients with HBV/HCV infection                         2152 / 255930           198 / 13864              0.561   (0.485-0.649)   \<0.0001

*n*: case number of incident lung cancer, *N*: case number followed

HR: hazard ratio, CI: confidence interval

COPD: chronic obstructive pulmonary disease, HP: Helicobacter pylori, EBV: Epstein-Barr virus, HBV: hepatitis B virus, HCV: hepatitis C virus

Table [4](#T4){ref-type="table"} shows the hazard ratios in different subgroups of age, sex, follow-up duration, the presence or absence of diagnoses of chronic obstructive pulmonary disease (COPD)/tobacco abuse, and the use of insulin, sulfonylurea, meglitinide, acarbose, rosiglitazone, pioglitazone, angio-tensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), calcium channel blocker, statin, fibrate and aspirin. All hazard ratios favored a lower risk of lung cancer associated with metformin use, even though the *P*-values were not significant for the subgroups who had been followed up for ≥5 years or had been using insulin, acarbose or rosiglitazone.

###### Subgroup analyses estimating hazard ratios for lung cancer for ever versus never users of metformin

  Model                             *n*/*N* in ever users   *n*/*N* in never users   HR      95% CI          *P* value
  --------------------------------- ----------------------- ------------------------ ------- --------------- -----------
  Age \<65 years                    1001 / 174601           105 / 7958               0.503   (0.403-0.628)   \<0.0001
  Age ≥65 years                     1364 / 105558           126 / 7456               0.734   (0.611-0.880)   0.0009
  Men                               1541 / 150517           133 / 8819               0.649   (0.544-0.775)   \<0.0001
  Women                             824 / 129642            78 / 6595                0.507   (0.402-0.639)   \<0.0001
  Follow-up duration \<5 years      2014 / 102702           184 / 6200               0.557   (0.479-0.647)   \<0.0001
  Follow-up duration ≥5 years       351 / 177457            27 / 9214                0.694   (0.469-1.027)   0.0676
  COPD and/or tobacco abuse: (+)    1614 / 141334           150 / 7831               0.557   (0.472-0.659)   \<0.0001
  COPD and/or tobacco abuse: (-)    751 / 138825            61 / 7583                0.649   (0.500-0.842)   0.0012
  Insulin use (+)                   42 / 5814               13 / 1243                0.629   (0.337-1.171)   0.1437
  Insulin use (-)                   2323 / 274345           198 / 14171              0.581   (0.502-0.672)   \<0.0001
  Sulfonylurea use (+)              1641 / 185722           162 / 11298              0.581   (0.494-0.682)   \<0.0001
  Sulfonylurea use (-)              724 / 94437             49 / 4116                0.606   (0.454-0.810)   0.0007
  Meglitinide use (+)               96 / 10100              19 / 1248                0.538   (0.329-0.879)   0.0135
  Meglitinide use (-)               2269 / 270059           192 / 14166              0.593   (0.512-0.687)   \<0.0001
  Acarbose use (+)                  147 / 14193             18 / 1713                0.857   (0.525-1.398)   0.5368
  Acarbose use (-)                  2218 / 265966           193 / 13701              0.566   (0.489-0.656)   \<0.0001
  Rosiglitazone use (+)             117 / 12833             7 / 469                  0.587   (0.274-1.258)   0.1709
  Rosiglitazone use (-)             2248 / 267326           204 / 14945              0.586   (0.508-0.677)   \<0.0001
  Pioglitazone use (+)              41 / 6779               7 / 391                  0.283   (0.127-0.630)   0.0020
  Pioglitazone use (-)              2324 / 273380           204 / 15023              0.597   (0.517-0.688)   \<0.0001
  ACEI/ARB use (+)                  1784 / 204108           155 / 10731              0.568   (0.482-0.669)   \<0.0001
  ACEI/ARB use (-)                  581 / 76051             56 / 4683                0.626   (0.476-0.824)   0.0008
  Calcium channel blocker use (+)   1557 / 166164           144 / 9705               0.592   (0.499-0.702    \<0.0001
  Calcium channel blocker use (-)   808 / 113995            67 / 5709                0.585   (0.456-0.751)   \<0.0001
  Statin use (+)                    1392 / 184811           85 / 8373                0.706   (0.567-0.879)   0.0018
  Statin use (-)                    973 / 95348             126 / 7041               0.549   (0.456-0.661)   \<0.0001
  Fibrate use (+)                   949 / 120199            67 / 5303                0.579   (0.452-0.742)   \<0.0001
  Fibrate use (-)                   1416 / 159960           144 / 10111              0.601   (0.506-0.714)   \<0.0001
  Aspirin use (+)                   1530 / 171328           119 / 8849               0.619   (0.514-0.746)   \<0.0001
  Aspirin use (-)                   835 / 108831            92 / 6565                0.534   (0.430-0.662)   \<0.0001

*n*: case number of incident lung cancer, *N*: case number followed

HR: hazard ratio, CI: confidence interval

COPD: chronic obstructive pulmonary disease, ACEI/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker

DISCUSSION {#s3}
==========

The findings supported a significantly lower risk of lung cancer in patients with T2DM who used metformin (Tables [2](#T2){ref-type="table"}-[4](#T4){ref-type="table"}).

The mechanisms for a reduced risk of lung cancer associated with metformin use remain to be explored. In general, metformin may exert its anticancer effect through the inhibition of tumor angiogenesis \[[@R30]\], suppressing cancer cell metabolism \[[@R31]\], activation of apoptosis and autophagy \[[@R32]\], inhibition of mammalian target of rapamycin (mTOR) \[[@R33]\], immunomodulation by increasing the number of CD8^+^ tumor-infiltrating lymphocytes \[[@R34]\], and impairing one-carbon metabolism acting like an antifolate drug \[[@R35]\].

Some *in vitro* and *in vivo* studies conducted in lung cancer cells specifically supported these potential mechanisms. The mTOR pathway is upregulated in non-small-cell lung cancer (NSCLC) and metformin inhibits its signaling by directly activating 5\' adenosine monophosphate-activated protein kinase (AMPK) via liver kinase B1 (LKB1) \[[@R36]\]. Metformin may also inhibit the growth of human NSCLC cells by activating AMPK via an LKB1-independent pathway \[[@R37]\]. In *in vitro* studies, metformin blocks the M2-like polarization of macrophages (important for cancer progression and metastasis) and inhibits metastasis of Lewis lung cancer \[[@R38]\]. Metformin can also act in combination with salinomycin (a putative stem cell killer) to eradicate the NSCLC monolayer cells \[[@R39]\] and sensitize lung cancer cells to chemotherapeutic agents \[[@R40]\]. A meta-analysis suggested that metformin therapy is associated with an improved outcome in lung cancer patients with diabetes \[[@R41]\].

There is a higher risk of lung cancer in patients with obesity \[[@R42]\]. It is interesting to observe an increased risk in the first tertiles of cumulative duration of metformin therapy (Table [2](#T2){ref-type="table"}). A residual confounding from obesity possibly explained such a result because metformin is considered as the first-line treatment for patients with T2DM, especially in those with obesity. Patients categorized in the first tertiles were short-term users and would be characterized by obesity when metformin was preferentially used. The increased risk associated with obesity in patients who were previously on diet control or treated with other medications might be carried over to these short-term users.

The present study has several strengths. First, all claims records of outpatient visits and hospital admission were included and the diagnoses were considered from both sources. Second, most medical co-payments can be waived by the NHI in patients with cancer, and there is a low drug cost-sharing in patients with certain conditions, such as those with a low-income household, veterans or patients with prescription refills for chronic disease. Therefore, the detection rate of lung cancer would be less biased by different social classes. Third, self-reporting bias was much reduced by the use of medical records.

The study limitations included a lack of actual measurement data for confounders such as anthropometric factors, smoking, alcohol drinking, family history, lifestyle, nutritional status, dietary pattern, and genetic parameters. In addition, we did not have exposure data of some occupational and environmental carcinogens and could not evaluate the impact of biochemical data. Another limitation is the lack of information on the pathology, grading and staging of lung cancer. Because adenocarcinoma represents 42% and 71% of all cases of lung cancer in men and women, respectively, in Taiwan \[[@R43]\], the findings should better be applied to adenocarcinoma rather than to squamous cell carcinoma, especially in females.

In summary, this study supports that metformin use in Taiwanese patients with T2DM may significantly reduce the risk of lung cancer, especially when it has been used for more than 4 years.

MATERIALS AND METHODS {#s4}
=====================

The NHI implemented in Taiwan since March 1995 is a compulsory and universal system of health insurance. It covers \>99% of Taiwan residents and has contracts with \>98% of the hospitals nationwide. The reimbursement databases are handled by the National Health Research Institutes and can be used for academic researches after proposal review and approval by an ethic review board. This study was granted with an approval number 99274.

Individuals were de-identified for the protection of privacy. Diabetes was coded 250.XX and lung cancer 162, based on the *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM).

Figure [1](#F1){ref-type="fig"} shows the procedures in selecting a cohort of patients with newly diagnosed T2DM (original sample) and a 1:1 matched-pairs of sample (matched sample) into the study. The patients should have been diagnosed as having diabetes at an onset age of 25-74 years during the period from 1999 to 2005. Patients with diabetes mellitus diagnosed during 1996-1998 were excluded to assure a first diagnosis of diabetes after 1999, and they should have been followed up in the outpatient clinic with prescription of antidiabetic drugs for 2 or more times (n=423949). In Taiwan, patients with type 1 diabetes can be waived of much of the co-payment after a certified diagnosis with issuance of a so-called "Severe Morbidity Card". These patients with type 1 diabetes (n=2400) were excluded because metformin is not indicated for them. Patients with missing data (n=746), with a diagnosis of any cancer before entry or within one year of diabetes diagnosis (n=45691), aged \<25 (n=19521) or ≥75 (n=43340) years, and followed up for \<365 days (n=16678) were also excluded. As a result, there were 280159 patients who had ever been treated with metformin and 15414 patients who had never been treated with metformin (the original sample).

Because the characteristics might be imbalanced between metformin ever users and never users in the original sample, additional analyses were conducted in a sample of 1:1 PS matched-pairs (the matched sample). The matched sample was created by using the Greedy 8 → 1 digit match algorithm proposed by Parsons (the matching macro using SAS statistical software is available online) \[[@R44]\]. The PS was derived from all characteristics listed in Table [1](#T1){ref-type="table"} plus the date of entry by using logistic regression. Because the case number of never users was much smaller than ever users in the original sample, the number of matched-pairs of ever and never users was based on the case number of never users in the original sample (i.e., n=15414). Therefore, one case in the pool of ever users in the original sample was selected as a matched-pair to each of the never users. According to the matching algorithm, the best match with the highest 8 digits of the PS was first selected. If a matched-pair was made, no more matching was considered. If not, ever users would then be matched on 7 digits of the PS to the never users. The procedures were repeated sequentially to the lowest digit of PS until a matched-pair was made \[[@R44]\]. This matching method has been used in our previous studies \[[@R10], [@R12], [@R20], [@R45], [@R46]\].

Cumulative duration (months) of metformin use was calculated and its tertiles were used. Demographic data of age, sex, occupation and living region, and factors that might be correlated with metformin use, diabetes severity or cancer risk were considered as potential confounders. The living region and occupation were classified as detailed elsewhere \[[@R13]\]. In brief, the living region was classified as Taipei, Northern, Central, Southern, and Kao-Ping/Eastern. Occupation was classified as class I (civil servants, teachers, employees of governmental or private businesses, professionals and technicians), class II (people without a specific employer, self-employed people or seamen), class III (farmers or fishermen) and class IV (low-income families supported by social welfare, or veterans).

Other confounders included 1) major comorbidities associated with diabetes mellitus: hypertension (ICD-9-CM code: 401-405), dyslipidemia (272.0-272.4) and obesity (278); 2) diabetes-related complications: nephropathy (580-589), eye disease (250.5, 362.0, 369, 366.41 and 365.44), stroke (430-438), ischemic heart disease (410-414), and peripheral arterial disease (250.7, 785.4, 443.81 and 440-448); 3) antidiabetic drugs: insulin, sulfonylurea, meglitinide, acarbose, rosiglitazone and pioglitazone; 4) potential risk factors of cancer: COPD (a surrogate of smoking; 490-496), tobacco abuse (305.1, 649.0 and 989.84), alcohol-related diagnoses (291, 303, 535.3, 571.0-571.3 and 980.0), history of *Helicobacter pylori* (HP) infection (defined below), diagnoses related to EBV infection (075, 710.3 and 710.4), HBV infection (070.22, 070.23, 070.32, 070.33 and V02.61) and hepatitis C virus infection (070.41, 070.44, 070.51, 070.54 and V02.62); and 5) medications that are commonly used in diabetes patients and may potentially affect cancer risk: ACEI/ARB, calcium channel blocker, statin, fibrate and aspirin. History of HP infection was defined based on one of the following two criteria: 1) having received an HP eradication therapy (detailed previously \[[@R47]\] and defined in brief as a combination use of proton pump inhibitors or H2 receptor blockers, plus clarithromycin, metronidazole or levofloxacin, plus amoxicillin or tetracycline, with or without bismuth, in the same prescription order for 7-14 days); and/or 2) HP infection diagnosis (041.86).

The characteristics between never users and ever users were compared by Student\'s t test for age and by Chi-square test for other variables. The standardized differences proposed by Austin and Stuart as a test for balance diagnostics were calculated for all covariates \[[@R48]\]. A value of \>10% might indicate potential confounding from the variable \[[@R48]\].

The incidence density of lung cancer was calculated for never users, ever users and tertiles of cumulative duration of metformin therapy. The numerator was the case number of incident lung cancer during follow-up, and the denominator was the person-years of follow-up. Follow-up started on the first day of the use of antidiabetic drugs and ended on December 31, 2011, at the time of a new diagnosis of lung cancer, or on the date of death or the last reimbursement record.

The treatment effect was estimated by Cox regression incorporated with IPTW using the PS \[[@R29]\]. Hazard ratios were estimated for ever versus never users and for each tertile of cumulative duration of metformin therapy using never users as referent.

Sensitivity analyses were conducted in the original sample by estimating the overall hazard ratios for ever versus never users after excluding patients with certain risk factors of cancer. These analyses were conducted after excluding 1) patients who developed other cancers during follow-up; 2) patients with COPD/tobacco abuse; 3) patients with alcohol-related diagnoses; and 4) patients with infections of HP, EBV and HBV/HCV, respectively.

Subgroup analyses were also conducted to examine the consistency of the findings. Hazard ratios were estimated for subgroups of age \<65 years, age ≥65 years, men, women, follow-up duration \< 5 years, follow-up duration ≥5 years, COPD/tobacco abuse (+), COPD/tobacco abuse (-) and with and without the use of certain medications (i.e., insulin, sulfonylurea, meglitinide, acarbose, rosiglitazone, pioglitazone, ACEI/ARB, calcium channel blocker, statin, fibrate and aspirin).

Analyses were conducted using SAS statistical software, version 9.3 (SAS Institute, Cary, NC). *P* \< 0.05 was considered statistically significant.

The study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of Bureau of National Health Insurance, Department of Health or National Health Research Institutes.
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